CCO Management Series
Practical Applications and Clinical Advances in Multiple Myeloma: Options Spanning the Spectrum of Care
Mechanisms of Action and Clinical Advances in the Treatment of Multiple Myeloma |
Module 1 of 2 |
 
- R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
- Joseph D. Tariman, PhC, MN, APRN, BC, OCN
|
|
|
R. Donald Harvey, PharmD, FCCP, BCPS, BCOP, and Joseph D. Tariman, PhC, APRN, BC, OCN, review safety, efficacy, and mechanistic data on current and potential future treatment options for patients with multiple myeloma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate data on the safety, efficacy, and pharmacokinetic properties of various classes of novel agents when caring for patients with multiple myeloma in both the frontline and relapsed/refractory settings
- Describe clinically relevant pharmacokinetic and efficacy differences between conventional doxorubicin and pegylated liposomal doxorubicin
- Compare the safety and efficacy of traditional approaches with combination regimens that include newer therapeutic agents
- Examine the clinical impact of modified dosing schedules in elderly patients with multiple myeloma
- Consider the underlying mechanisms of action of available agents in treating patients who experience adverse effects from therapy
Abstract
|
Clinical Considerations and Implications for Optimizing Patient Outcomes in Multiple Myeloma |
Module 2 of 2 |
- Joseph D. Tariman, PhC, MN, APRN, BC, OCN
- R. Donald Harvey, PharmD, FCCP, BCPS, BCOP
|
|
|
R. Donald Harvey, PharmD, FCCP, BCPS, BCOP, and Joseph D. Tariman, PhC, MN, APRN, BC, OCN, review nursing considerations and strategies to manage adverse events of current and emerging treatments for patients with multiple myeloma.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recognize the signs, symptoms, and risk factors of toxicities commonly associated with the various classes of current and novel agents used for the treatment of multiple myeloma
- Describe recommended strategies for managing adverse events of systemic therapy for multiple myeloma
- Consider appropriate prophylactic measures to minimize cardiotoxic adverse events in patients receiving treatment for multiple myeloma
- Educate patients regarding potential adverse events and interactions and strategies to manage these occurrences to optimize treatment efficacy
Abstract
|
Interactive Virtual Presentations
Newly Diagnosed Multiple Myeloma in Transplantation-Eligible Patients
|
|
|
Jean-Luc Harousseau, MD, explores recent thinking and new clinical trial data shaping the treatment of myeloma patients who are eligible for stem cell transplantation.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the role of autologous stem cell transplantation in the era of novel agents for the treatment of multiple myeloma
- Compare maintenance therapies for transplantation-eligible patients with multiple myeloma
- Contrast induction strategies for transplantation-eligible patients with multiple myeloma
- Analyze the effect of achieving a complete remission plus a very good partial response on outcomes in patients with multiple myeloma
|
Slideset: Newly Diagnosed Multiple Myeloma in Transplantation-Eligible Patients
 |
|
Download a presentation by Jean-Luc Harousseau, MD, to review frontline treatment strategies to optimize outcomes in patients with multiple myeloma who are candidates for autologous stem cell transplantation.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.55 MB
| Date posted: 8/27/2009
|
Treatment of Newly Diagnosed Myeloma Patients Who Are Not Candidates for ASCT
- Jesús F. San-Miguel, MD, PhD
|
|
|
In this interactive program, Jesús F. San Miguel, MD, PhD, discusses optimal treatment approaches for myeloma patients ineligible for transplantation and provides evidence-based data supporting these choices.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Evaluate the efficacy and safety of current and novel options for the treatment of myeloma patients ineligible for transplantation
- Analyze the clinical application of therapeutic approaches for treating multiple myeloma patients ineligible for transplantation and how to optimally integrate them into clinical practice
- Evaluate novel combination approaches for the treatment of myeloma patients ineligible for transplantation and how they may affect clinical practice
|
Slideset: Treatment of Newly Diagnosed Myeloma Patients Who Are Not Candidates for ASCT
 |
|
Download a presentation by Jesús F. San Miguel, MD, PhD, to explore optimal treatment approaches for myeloma patients ineligible for transplantation and review evidence-based data supporting these choices.
Format: Microsoft PowerPoint (.ppt) |
File size: 3.65 MB
| Date posted: 9/22/2009
|
Treatment of Patients With Relapsed or Refractory Multiple Myeloma
- Robert Z. Orlowski, MD, PhD
|
|
|
Robert Z. Orlowski, MD, PhD, explores optimal treatment approaches for patients with relapsed/refractory multiple myeloma and reviews supporting evidence in this interactive presentation.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Describe the results of retreatment with proteasome inhibitors in the setting of relapsed/refractory multiple myeloma
- Discuss salvage therapy with immunomodulatory agents in the setting of relapsed/refractory multiple myeloma
- Illustrate the clinical course of a patient with myeloma that relapses
|
Slideset: Treatment of Patients With Relapsed or Refractory Multiple Myeloma
 |
|
Explore optimal treatment approaches for patients with relapsed/refractory multiple myeloma and review supporting evidence with Robert Z. Orlowski, MD, PhD in this downloadable slide presentation.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.12 MB
| Date posted: 10/20/2009
|
CCO Slideset
Pharmacological and Clinical Nursing Considerations in the Treatment of Multiple Myeloma
 |
|
Download a presentation by R. Donald Harvey, PharmD, FCCP, BCPS, BCOP, and Joseph D. Tariman, PhC, MN, APRN, BC, OCN, to review the pharmacologic profiles of agents for the treatment of myeloma and strategies to manage adverse events to optimize treatment outcomes for patients with multiple myeloma.
Format: Microsoft PowerPoint (.ppt) |
File size: 2.30 MB
| Date posted: 8/4/2009
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grant provided by:
Educational grants support only the CME-certified components of this program.
|